{
}
Barclays has downgraded Coloplast A/S from Overweight to Equalweight, lowering the price target to DKK750 due to execution issues and a recent profit warning. The stock has dropped 12.23% in the past week, nearing its 52-week low, amid concerns over leadership uncertainty and mid-term targets. Other analysts have also adjusted their ratings, reflecting a mixed outlook for the company, with some upgrades citing potential long-term growth driven by innovations and reimbursement reforms.
Coloplast A/S has faced a decline in its share price, recently falling to EUR 112.38, reflecting a 4.66% loss over the month. The company, which specializes in medical products for urology and wound care, announced the sale of its skin care division to refocus on core competencies. Despite recent challenges, the share has shown an annual increase of 8.10%.
UBS has upgraded Coloplast A/S to a "neutral" rating from "sell," citing improved market dynamics and a reassessment of risks. The firm noted reduced competitive pressures and a more conservative market outlook, with expectations of steady growth, projecting an 8% annual revenue increase and an 11% rise in earnings per share from 2024 to 2028. The stock is now trading at a 40% sector premium, aligning with historical averages, and UBS set a price target of DKK 858, reflecting a valuation of 33 times estimated 2025 earnings.
UBS has upgraded Coloplast A/S to a "neutral" rating from "sell," citing improved market dynamics and reduced risks associated with the company's operations. The revision reflects a reassessment of competitive pressures and growth investments, particularly in wound biologics and continence care. Analysts project an 8% compound annual revenue growth rate and an 11% increase in earnings per share from 2024 to 2028, with the stock trading at a 40% sector premium.
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales divided into hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and voice and respiratory care (7.9%). Geographically, sales are primarily from the United States (21%), the United Kingdom (14%), and other regions (52.8%).
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales primarily from hygiene products (43.4%), ostomy care (36.8%), wound care (11.9%), and voice/respiratory care (7.9%). Geographically, sales are led by the U.S. (21%), the U.K. (14%), and France (10.8%).
UBS has upgraded Coloplast to a neutral rating while maintaining its price target at DKK 858, citing reduced risks following the recent sale of its skin care business, which led to a 1% cut in sales estimates. The company specializes in disposable medical products, with significant sales in the USA and UK.
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales primarily from hygiene products (43.4%), ostomy care (36.8%), wound care (11.9%), and voice/respiratory care (7.9%). Geographically, sales are led by the U.S. (21%), the U.K. (14%), and France (10.8%).
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales primarily from hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and voice and respiratory care (7.9%). Geographically, sales are led by the United States (21%), the United Kingdom (14%), and France (10.8%), with other regions accounting for 52.8%.
UBS has upgraded Coloplast to a neutral rating while maintaining a price target of DKK 858. Coloplast A/S focuses on disposable medical products, with sales divided into hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and vocal and respiratory care (7.9%). Geographically, the company generates 1.4% of sales in Denmark, 21% in the USA, 14% in the UK, 10.8% in France, and 52.8% from other regions.
Coloplast A/S
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
barclays downgrades coloplast stock amid leadership changes and profit warning
08:39 07.05.2025
Coloplast Faces Stock Decline Amid Strategic Shift and Market Challenges
01:12 12.12.2024
ubs upgrades coloplast to neutral amid improved market dynamics and growth prospects
15:00 11.12.2024
UBS Upgrades Coloplast to Neutral Amid Improved Market Dynamics and Growth Prospects
15:00 11.12.2024
UBS Upgrades Coloplast to Neutral Amid Diverse Medical Product Offerings
10:53 11.12.2024
UBS Upgrades Coloplast to Neutral Amid Diverse Medical Product Portfolio
10:38 11.12.2024
UBS Upgrades Coloplast to Neutral Following Skin Care Business Sale
10:38 11.12.2024
ubs upgrades coloplast to neutral amid diverse medical product offerings
10:38 11.12.2024
UBS Upgrades Coloplast to Neutral Amid Diverse Medical Product Portfolio
10:38 11.12.2024
UBS Upgrades Coloplast to Neutral with Price Target of DKK 858
09:55 11.12.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: